These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24738644)

  • 1. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
    Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
    Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD-DPC.
    Yamashita Y; Morimoto T; Yoshikawa Y; Yaku H; Sumita Y; Nakai M; Ono K; Kimura T
    J Am Heart Assoc; 2020 Jan; 9(2):e014582. PubMed ID: 31918600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
    Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in centenarians: Findings from the RIETE registry.
    Lacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M;
    Eur J Intern Med; 2016 Dec; 36():62-66. PubMed ID: 27495947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of anticoagulation after venous thromboembolism diagnoses during delivery hospitalizations.
    O'Shaugnessy F; Syeda SK; Huang Y; D'Alton ME; Wen T; Wright JD; Friedman AM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6353-6355. PubMed ID: 33855935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry.
    Alatri A; Mazzolai L; Font C; Tafur A; Valle R; Marchena PJ; Ballaz A; Tiraferri E; Font L; Monreal M; Riete Investigators T
    Thromb Haemost; 2017 Jul; 117(8):1630-1636. PubMed ID: 28517021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting.
    Kozak PM; Xu M; Farber-Eger E; Gailani D; Wells QS; Beckman JA
    J Am Heart Assoc; 2019 Nov; 8(22):e013395. PubMed ID: 31696751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
    Burton T; Hlavacek P; Guo JD; Rosenblatt L; Mardekian J; Ferri M; Russ C; Kline JA
    Hosp Pract (1995); 2020 Oct; 48(4):196-205. PubMed ID: 32720816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
    van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
    Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis.
    Becattini C; Giustozzi M; Cerdà P; Cimini LA; Riera-Mestre A; Agnelli G
    J Thromb Haemost; 2019 Aug; 17(8):1217-1228. PubMed ID: 31063646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
    Novacek G; Weltermann A; Sobala A; Tilg H; Petritsch W; Reinisch W; Mayer A; Haas T; Kaser A; Feichtenschlager T; Fuchssteiner H; Knoflach P; Vogelsang H; Miehsler W; Platzer R; Tillinger W; Jaritz B; Schmid A; Blaha B; Dejaco C; Eichinger S
    Gastroenterology; 2010 Sep; 139(3):779-87, 787.e1. PubMed ID: 20546736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.